These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 30910382)

  • 21. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization.
    Leung WH; Gay J; Martin U; Garrett TE; Horton HM; Certo MT; Blazar BR; Morgan RA; Gregory PD; Jarjour J; Astrakhan A
    JCI Insight; 2019 Apr; 5(11):. PubMed ID: 31039141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.
    Kueberuwa G; Zheng W; Kalaitsidou M; Gilham DE; Hawkins RE
    J Vis Exp; 2018 Oct; (140):. PubMed ID: 30394400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype.
    Gargett T; Truong N; Ebert LM; Yu W; Brown MP
    Cytotherapy; 2019 Jun; 21(6):593-602. PubMed ID: 30975603
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Closed-system manufacturing of CD19 and dual-targeted CD20/19 chimeric antigen receptor T cells using the CliniMACS Prodigy device at an academic medical center.
    Zhu F; Shah N; Xu H; Schneider D; Orentas R; Dropulic B; Hari P; Keever-Taylor CA
    Cytotherapy; 2018 Mar; 20(3):394-406. PubMed ID: 29287970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Establishment of a New Cryopreservation Solution for Chimeric Antigen Receptor T Cells.
    Tang Q; Gu L; Zhou B; Shi J; Wu H; Zhu H; Xu Y; Zhang T
    Biopreserv Biobank; 2022 Dec; 20(6):567-574. PubMed ID: 35294840
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of chimeric antigen receptor surface expression by a small molecule switch.
    Juillerat A; Tkach D; Busser BW; Temburni S; Valton J; Duclert A; Poirot L; Depil S; Duchateau P
    BMC Biotechnol; 2019 Jul; 19(1):44. PubMed ID: 31269942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basic Procedures for Detection and Cytotoxicity of Chimeric Antigen Receptors.
    Mihara K; Yoshida T; Bhattacharyya J
    Methods Mol Biol; 2019; 1904():299-306. PubMed ID: 30539476
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Streamlined measurement of chimeric antigen receptor T-cell concentration, size, viability and two-color phenotyping during manufacturing.
    Pajarillo R; Paruzzo L; Carturan A; Ugwuanyi O; White G; Guruprasad P; Ballard HJ; Patel RP; Zhang Y; Lee YG; Hong SJA; Dittami GM; Ruella M
    Cytotherapy; 2024 May; 26(5):506-511. PubMed ID: 38483365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer.
    Jiang H; Shi Z; Wang P; Wang C; Yang L; Du G; Zhang H; Shi B; Jia J; Li Q; Wang H; Li Z
    J Natl Cancer Inst; 2019 Apr; 111(4):409-418. PubMed ID: 30203099
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Humanization of the antigen-recognition domain does not impinge on the antigen-binding, cytokine secretion, and antitumor reactivity of humanized nanobody-based CD19-redirected CAR-T cells.
    Safarzadeh Kozani P; Safarzadeh Kozani P; Rahbarizadeh F
    J Transl Med; 2024 Jul; 22(1):679. PubMed ID: 39054481
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In Vitro Differentiation of T Cell: From CAR-Modified T-iPSC.
    Ueda T; Kaneko S
    Methods Mol Biol; 2019; 2048():85-91. PubMed ID: 31396933
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Measuring Chimeric Antigen Receptor T Cells (CAR T Cells) Activation by Coupling Intracellular Cytokine Staining with Flow Cytometry.
    Xu C; Yin Y
    Methods Mol Biol; 2020; 2108():159-165. PubMed ID: 31939179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of Automated Separation, Expansion, and Quality Control Protocols for Clinical-Scale Manufacturing of Primary Human NK Cells and Alpharetroviral Chimeric Antigen Receptor Engineering.
    Oberschmidt O; Morgan M; Huppert V; Kessler J; Gardlowski T; Matthies N; Aleksandrova K; Arseniev L; Schambach A; Koehl U; Kloess S
    Hum Gene Ther Methods; 2019 Jun; 30(3):102-120. PubMed ID: 30997855
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
    Yoo HJ; Liu Y; Wang L; Schubert ML; Hoffmann JM; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Mokhir A; Schmitt M; Sellner L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31109083
    [TBL] [Abstract][Full Text] [Related]  

  • 38. GMP CAR-T cell production.
    Gee AP
    Best Pract Res Clin Haematol; 2018 Jun; 31(2):126-134. PubMed ID: 29909913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro CAR-T cell killing: validation of the potency assay.
    Piccinini C; Carloni S; Arienti C; Pancisi E; Fanini F; Pignatta S; Soldati V; Stefanelli M; Granato AM; Martinelli G; Ridolfi L; Petrini M
    Cancer Immunol Immunother; 2024 Jul; 73(9):168. PubMed ID: 38953939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma.
    Wang Y; Yu W; Zhu J; Wang J; Xia K; Liang C; Tao H
    J Exp Clin Cancer Res; 2019 Apr; 38(1):168. PubMed ID: 30995926
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.